Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-05-11
DOI
10.3389/fonc.2021.678634
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Characterisation of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial
- (2020) Rakesh Popat et al. HAEMATOLOGICA
- DREAMM-1 Patient perspectives from the first-in-human study of single-agent belantamab mafodotin for relapsed and refractory multiple myeloma (RRMM).
- (2020) Laurie Eliason et al. JOURNAL OF CLINICAL ONCOLOGY
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
- (2020) Nina Shah et al. Journal for ImmunoTherapy of Cancer
- Belantamab Mafotodin-Induced Epithelial Keratopathy Masquerading Myopic Surgery
- (2020) Antoine Rousseau et al. OPHTHALMOLOGY
- PCN309 Methodology for Evaluating Meaningful Change Thresholds in Patient-Reported Outcome (PRO) Measures for Corneal Events in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Receiving Single-Agent Belantamab Mafodotin (BELAMAF)
- (2020) L. Eliason et al. VALUE IN HEALTH
- Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study
- (2019) Suzanne Trudel et al. Blood Cancer Journal
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
- (2019) Sagar Lonial et al. LANCET ONCOLOGY
- Identification of novel macropinocytosis inhibitors using a rational screen of FDA-approved drugs
- (2018) Hui-Ping Lin et al. BRITISH JOURNAL OF PHARMACOLOGY
- Bortezomib ocular toxicities: Outcomes with ketotifen
- (2018) Michael Dennis et al. AMERICAN JOURNAL OF HEMATOLOGY
- Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine
- (2018) Ursula A Matulonis et al. CLINICAL CANCER RESEARCH
- Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial
- (2018) Suzanne Trudel et al. LANCET ONCOLOGY
- Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads
- (2017) Joanna C. Masters et al. INVESTIGATIONAL NEW DRUGS
- APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment
- (2016) Y.-T. Tai et al. BLOOD
- Ocular Adverse Events Associated with Antibody–Drug Conjugates in Human Clinical Trials
- (2015) Joshua Seth Eaton et al. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
- Current ADC Linker Chemistry
- (2015) Nareshkumar Jain et al. PHARMACEUTICAL RESEARCH
- Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma
- (2014) Nizar M. Tannir et al. INVESTIGATIONAL NEW DRUGS
- B-cell maturation antigen is modified by a single N-glycan chain that modulates ligand binding and surface retention
- (2013) H.-W. Huang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started